JP2023526923A5 - - Google Patents

Info

Publication number
JP2023526923A5
JP2023526923A5 JP2022569264A JP2022569264A JP2023526923A5 JP 2023526923 A5 JP2023526923 A5 JP 2023526923A5 JP 2022569264 A JP2022569264 A JP 2022569264A JP 2022569264 A JP2022569264 A JP 2022569264A JP 2023526923 A5 JP2023526923 A5 JP 2023526923A5
Authority
JP
Japan
Prior art keywords
raav
pharmaceutical composition
patient
composition according
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032451 external-priority patent/WO2021231863A1/en
Publication of JP2023526923A publication Critical patent/JP2023526923A/ja
Publication of JP2023526923A5 publication Critical patent/JP2023526923A5/ja
Pending legal-status Critical Current

Links

JP2022569264A 2020-05-14 2021-05-14 ポンペ病の治療に有用な組成物 Pending JP2023526923A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063024941P 2020-05-14 2020-05-14
US63/024,941 2020-05-14
US202063109677P 2020-11-04 2020-11-04
US63/109,677 2020-11-04
US202163180379P 2021-04-27 2021-04-27
US63/180,379 2021-04-27
PCT/US2021/032451 WO2021231863A1 (en) 2020-05-14 2021-05-14 Compositions useful for treatment of pompe disease

Publications (2)

Publication Number Publication Date
JP2023526923A JP2023526923A (ja) 2023-06-26
JP2023526923A5 true JP2023526923A5 (https=) 2024-05-23

Family

ID=78525047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569264A Pending JP2023526923A (ja) 2020-05-14 2021-05-14 ポンペ病の治療に有用な組成物

Country Status (13)

Country Link
US (1) US20230173108A1 (https=)
EP (1) EP4149519A4 (https=)
JP (1) JP2023526923A (https=)
KR (1) KR20230010255A (https=)
CN (1) CN115916334A (https=)
AU (1) AU2021273273A1 (https=)
BR (1) BR112022022704A2 (https=)
CA (1) CA3177954A1 (https=)
CL (1) CL2022003132A1 (https=)
CO (1) CO2022017224A2 (https=)
IL (1) IL298178A (https=)
MX (1) MX2022014255A (https=)
WO (1) WO2021231863A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003687A1 (en) * 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024151982A1 (en) * 2023-01-13 2024-07-18 Amicus Therapeutics, Inc. Gene therapy constructs for the treatment of pompe disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
US20120322861A1 (en) * 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
KR20230066482A (ko) * 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
PL3097197T3 (pl) * 2014-01-21 2021-06-28 Vrije Universiteit Brussel Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie
US20170037431A1 (en) * 2014-05-01 2017-02-09 University Of Washington In vivo Gene Engineering with Adenoviral Vectors
EP2960336A1 (en) * 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
WO2018178067A1 (en) * 2017-03-27 2018-10-04 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
RU2770922C2 (ru) * 2017-09-20 2022-04-25 4Д Молекьюлар Терапьютикс Инк. Капсиды вариантов аденоассоциированных вирусов и методы их применения
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
JP7585233B2 (ja) * 2019-04-30 2024-11-18 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ポンペ病の治療のために有用な組成物

Similar Documents

Publication Publication Date Title
JP2022502046A5 (https=)
CN111718947B (zh) 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
JP2022530833A5 (https=)
SG11202111400TA (en) Compositions useful for treatment of pompe disease
IL282053B2 (en) Constructions of glut1-linked recombinant aav vectors, preparations and kits containing them and their use
JP2022530824A5 (https=)
US20020076754A1 (en) Overcoming AAV vector size limitation through viral DNA hetero-dimerization
US12171794B2 (en) Gene therapy for ciliopathies
JP2023526923A5 (https=)
JP2022512589A5 (https=)
CA3173768A1 (en) Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
US20230220420A1 (en) Gene therapy for bardet-biedl syndrome
EP4368203A1 (en) Construction and use of anti-vegf antibody in-vivo expression system
IL324272A (en) Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders
JP2023551254A5 (https=)
JP2022530359A5 (https=)
JP2022523050A5 (https=)
US20240076691A1 (en) Codon-optimized nucleic acid encoding the fix protein
WO1998043665A1 (fr) Agent preventif et/ou therapeutique pour les maladies des reins
HK40096161A (zh) 一种用於遗传性凝血因子缺乏病治疗的核酸构建体及其用途
HK40096161B (zh) 一种用於遗传性凝血因子缺乏病治疗的核酸构建体及其用途
HK40108451A (zh) 一种用於遗传性凝血因子缺乏病治疗的核酸构建体
HK40091511A (zh) 一种抗vegf抗体体内表达系统的构建和应用
HK40087843A (zh) 用於治疗庞贝氏病和溶酶体紊乱的包含肝特异性启动子的治疗性腺相关病毒